Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer

INTRODUCTION: Mutations affecting p53 or its upstream activator Chk2 are associated with resistance to DNA-damaging chemotherapy in breast cancer. ATM (Ataxia Telangiectasia Mutated protein) is the key activator of p53 and Chk2 in response to genotoxic stress. Here, we sought to evaluate ATM's...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Knappskog, Stian, Chrisanthar, Ranjan, Løkkevik, Erik, Anker, Gun, Østenstad, Bjørn, Lundgren, Steinar, Risberg, Terje, Mjaaland, Ingvil, Leirvaag, Beryl, Miletic, Hrvoje, Lønning, Per E
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2012
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3446381/
https://ncbi.nlm.nih.gov/pubmed/22420423
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/bcr3147
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller